Mycofenolate Mofetil Aurobindo (Mycophenolate Mofetil)

Mycophenolate Mofetil, the active ingredient in Mycofenolate Mofetil Aurobindo, is an antimetabolite immunosuppressant presented as an oral formulation for oral use. It is employed to prevent graft rejection after solid organ transplantation and to treat certain autoimmune diseases such as lupus nephritis. GNH USA supplies Mycofenolate Mofetil Aurobindo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.

Mycophenolate Mofetil acts on the immune system to reduce lymphocyte proliferation, making it useful in transplant and autoimmune settings. - Prevention of graft rejection in solid organ transplantation: lowers the incidence of acute and chronic rejection episodes. - Lupus nephritis: helps control renal inflammation and preserve kidney function. - Other autoimmune diseases (e.g., rheumatoid arthritis): used as an adjunct immunosuppressive therapy when standard treatments are insufficient.

Mycofenolate Mofetil may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: loose stools that may be watery. - Headache: intermittent mild to moderate pain. - Tremor: fine shaking of hands or limbs. - Abdominal pain: cramping or discomfort.

Serious or Rare Side Effects: - Leukopenia or anemia: significant reduction in blood cell counts. - Severe infections: opportunistic bacterial, viral or fungal infections. - Hepatic toxicity: elevated liver enzymes or hepatitis. - Malignancy risk: increased incidence of certain cancers with long‑term use. - Severe allergic reactions: rash, angioedema or anaphylaxis.

Before initiating therapy, several safety considerations should be addressed. - Monitor blood counts: perform regular CBC to detect leukopenia or anemia. - Assess renal function: adjust dose in patients with impaired kidney function. - Screen for infections: avoid starting therapy in the presence of active uncontrolled infections. - Pregnancy considerations: discuss potential risks with the prescriber; use only if benefits outweigh risks. - Vaccinations: avoid live vaccines while on treatment. - Store at below 25°C: keep in the original packaging, protect from moisture and light.

Mycophenolate Mofetil can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Antimetabolites (e.g., azathioprine): additive bone‑marrow suppression. - Live vaccines: heightened risk of infection.

Moderate Interactions (Monitor Closely): - Strong CYP3A4 inducers (e.g., rifampin): may reduce mycophenolate exposure. - Calcineurin inhibitors (cyclosporine, tacrolimus): can increase mycophenolate plasma levels. - Warfarin: may enhance anticoagulant effect, requiring INR monitoring.